|
|
Volumn 21, Issue 1, 2003, Pages 6-7
|
|
New products highlight ambiguity of orphan drug law
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGALSIDASE ALFA;
AGALSIDASE BETA;
ALPHA GALACTOSIDASE;
ISOENZYME;
ARTICLE;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MANUFACTURE;
ECONOMIC ASPECT;
ECONOMICS;
FABRY DISEASE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGAL ASPECT;
LICENSING;
METHODOLOGY;
STANDARD;
UNITED STATES;
ALPHA-GALACTOSIDASE;
CLINICAL TRIALS;
DRUG INDUSTRY;
ECONOMIC COMPETITION;
FABRY DISEASE;
HUMANS;
ISOENZYMES;
LEGISLATION, DRUG;
LICENSURE;
ORPHAN DRUG PRODUCTION;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0037591617
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0103-6b Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
